A practical reference on MC4R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-31. Anything still debated is marked as such rather than presented as settled.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
=== Off-label drugs === Antihistamines (histamine H1 receptor antagonists) (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) Corticosteroids (corticosteroid receptor agonists) (e.g., hydrocortisone, prednisone, triamcinolone acetonide) Hydroquinone – tyrosinase inhibitor and skin-lightening agent Nicotinamide (niacinamide) – vitamin B3 Oral antiandrogens (androgen receptor antagonists) (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide, ketoconazole, cimetidine) Other antibiotics (e.g., erythromycin, metronidazole, sulfacetamide) Other ethinylestradiol-containing combined oral contraceptives Salicylic acid – various actions (keratolytic, comedolytic, and bacteriostatic) Zinc – undefined mechanism of action (antibacterial and anti-inflammatory)
== Binding (drug distribution) == A drug in blood exists in two forms: bound and unbound. Depending on a specific drug's affinity for plasma proteins, a proportion of the drug may become bound to the proteins, with the remainder being unbound. If the protein binding is reversible, then a chemical equilibrium will exist between the bound and unbound states, such that:
== External links == FABP4+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human FABP4 genome location and FABP4 gene details page in the UCSC Genome Browser. PDBe-KB provides an overview of all the structure information available in the PDB for Human Fatty acid-binding protein, adipocyte PDBe-KB provides an overview of all the structure information available in the PDB for Mouse Fatty acid-binding protein, adipocyte
=== Additional surface methods === The SELDI process is a combination of surface-enhanced neat desorption (SEND),surface-enhanced affinity-capture (SEAC), and surface-enhanced photolabile attachment and release (SEPAR) mass spectrometry. With SEND, analytes can be desorbed and ionized without adding a matrix; the matrix is incorporated into the sample surface. In SEAC, the sample surface is modified to bind the analyte of interest for analysis with laser desorption/ionization mass spectrometry (LDI-MS). SEPAR is a combination of SEND and SEAC; the modified sample surface also acts as an energy absorbing matrix for ionization.
Sources: en.wikipedia.org
A sector-type mass analyzer uses a static electric and/or magnetic field to control the path of the ion beam. The most common type uses a magnetic field. In a simplified case, the field is a constant field
Epistles 13–14 of the first part of the Epistles of Wisdom focus on Jesus, detailing his ministry, his crucifixion by the Jews, and his descent from the cross. According to these epistles, Hamza bin Ali took him down from the cross and allowed him to return to his family, with the aim of preparing people to preach his religion. The epistle titled "Excuses and Warnings" foretells that, as a sign of the end times, Messiah Jesus "the son of Joseph and Mary", will appear in Egypt. The Jews will seize control of Jerusalem and seek revenge on the inhabitants of both Jerusalem and Acre. Subsequently, Messiah Jesus will expel the Jews from Jerusalem, and Christians will dominate Muslims until the Day of Judgment, when the divine Al-Hakim bi-Amr Allah returns to judge humanity. The author of the epistle "The Report of the Jewish and Christians" (Khabar al-Yahud wal Nasara), part of first volume of the Epistles of Wisdom, appears to have been a Druze individual. The account itself identifies him as Hamza ibn Ali, a supporter of al-Hakim's divinity and the founder of the Druze faith. Hamza ibn Ali reportedly died after al-Hakim's disappearance in 1021. In the 18th century, the Orientalist Jean Michel de Venture de Paradis mentioned obtaining a manuscript discovered in a Druze village. This manuscript contained, among other things, a description of a dialogue between al-Hakim and leaders of the Christian and Jewish communities. Additionally, it included eight letters written by al-Hakim's lieutenant, Hamza ibn Ali, with the final one titled "The Report of the Jewish and Christians".
== Formulations and trade names == Papaverine is available in its salt form as the hydrochloride, codecarboxylate, adenylate, and teprosylate. It was also once available as a salt of hydrobromide, camsylate, cromesilate, nicotinate, and phenylglycolate. The hydrochloride salt is available for intramuscular, intravenous, rectal and oral administration. The teprosylate is available in intravenous, intramuscular, and orally administered formulations. The codecarboxylate is available in oral form, only, as is the adenylate. The codecarboxylate is sold under the name Albatran, the adenylate as Dicertan, and the hydrochloride salt is sold variously as Artegodan (Germany), Cardioverina (countries outside Europe and the United States), Dispamil (countries outside Europe and the United States), Opdensit (Germany), Panergon (Germany), Paverina Houde (Italy, Belgium), Pavacap (United States), Pavadyl (United States), Papaverine (Israel), Papaverin-Hamelin (Germany), Paveron (Germany), Spasmo-Nit (Germany), Cardiospan, Papaversan, Cepaverin, Cerespan, Drapavel, Forpaven, Papalease, Pavatest, Paverolan, Therapav (Canada), Vasospan, Cerebid, Delapav, Dilaves, Durapav, Dynovas, Optenyl, Pameion, Papacon, Pavabid, Pavacen, Pavakey, Pavased, Pavnell, Alapav, Myobid, Vasal, Pamelon, Pavadel, Pavagen, Ro-Papav, Vaso-Pav, Papanerin-hcl, Qua bid, Papital T.R., Paptial T.R., Pap-Kaps-150. In Hungary, papaverine and homatropine methylbromide are used in mild drugs that help "flush" the bile.
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.